Literature DB >> 18160517

Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.

David Sevillano1, Lorenzo Aguilar, Luis Alou, María-José Giménez, Martha Torrico, Natalia González, Fabio Cafini, María-Teresa Relaño, Pilar Coronel, José Prieto.   

Abstract

Activity of simulated cefditoren urinary concentrations was determined against seven Escherichia coli isolates. Bactericidal activity was obtained from 4 to 24 h against TEM-1 (penicillinase production/hyperproduction), TEM-34 (IRT-6), and TEM-116 (extended-spectrum beta-lactamase [ESBL]) and from 6 to 8 h against SHV/TEM-116 (ESBL) but never against SHV/TEM-1 (ESBL). Extension of bactericidal activity depended on the resistance genotype/phenotype tested.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18160517      PMCID： PMC2258530          DOI： 10.1128/AAC.01247-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

Authors:  Jesús Rodríguez-Baño; Maria Dolores Navarro; Luisa Romero; Luis Martínez-Martínez; Miguel A Muniain; Evelio J Perea; Ramón Pérez-Cano; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.

Authors:  M Torrico; L Aguilar; N González; M J Giménez; O Echeverría; F Cafini; D Sevillano; L Alou; P Coronel; J Prieto
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

4.  [Phenotypes of resistance in community urinary tract isolates of Escherichia coli: therapeutic implications].

Authors:  Mercedes Alonso Sanz; M Isabel Abad Bécquer
Journal:  Med Clin (Barc)       Date:  2003-03-22       Impact factor: 1.725

5.  Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.

Authors:  Branka Bedenic; Jasmina Vranes; Sandra Suto; Zivojin Zagar
Journal:  Int J Antimicrob Agents       Date:  2005-06       Impact factor: 5.283

6.  [Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study].

Authors:  Antonia Andreu; Juan Ignacio Alós; Miguel Gobernado; Francesc Marco; Manuel de la Rosa; José Antonio García-Rodríguez
Journal:  Enferm Infecc Microbiol Clin       Date:  2005-01       Impact factor: 1.731

7.  Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.

Authors:  R N Jones; D J Biedenbach; D M Johnson
Journal:  Diagn Microbiol Infect Dis       Date:  2000-06       Impact factor: 2.803

8.  Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States.

Authors:  James A Karlowsky; Laurie J Kelly; Clyde Thornsberry; Mark E Jones; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  An in vitro characterization of cefditoren, a new oral cephalosporin.

Authors:  D Felmingham; M J Robbins; G Ghosh; H Bhogal; M D Mehta; A Leakey; S Clark; C A Dencer; G L Ridgway; R N Grüneberg
Journal:  Drugs Exp Clin Res       Date:  1994

10.  In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem.

Authors:  E Sakagawa; M Otsuki; T Oh; T Nishino; T Ou
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790
View more
  1 in total

1.  Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients.

Authors:  Despina Hatzaki; Garyphallia Poulakou; Ioannis Katsarolis; Niki Lambri; Maria Souli; Ioannis Deliolanis; Georgios K Nikolopoulos; Evangelia Lebessi; Helen Giamarellou
Journal:  BMC Infect Dis       Date:  2012-09-25       Impact factor: 3.090
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.